NEW YORK (GenomeWeb) - Biocept reported today after the close of the market that its first quarter revenues rose to $150,000 compared to $28,000 in Q1 2014, with the increase primarily due to growing commercial liquid biopsy test volumes.

The San Diego-based firm, which sells molecular diagnostic tests based on circulating tumor cells and circulating tumor DNA, said it tested 247 commercial cases during the first quarter of 2015, up from 11 commercial cases during the first quarter of 2014.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

US Attorney General Jeff Sessions is considering using DNA tests to determine relatedness between adult and child migrants, the Daily Caller reports.

Bloomberg reports that Brainstorm Cell Therapeutics plans to offer a treatment it is developing under the "right to try" law for hundreds of thousands of dollars.

In Nature this week: expansion of disease-resistance genes among long-lived oak trees, and more.

In a proof-of-concept study, researchers report being able to determine age from dried bloodstains, Discover's D-brief blog reports.